
Bayer’s Sevabertinib Earns Breakthrough Therapy Designation in U.S. and China for First-Line HER2-Mutant NSCLC
U.S. and China Grant Breakthrough Therapy Designation to Bayer’s Sevabertinib as First-Line Therapy for HER2-Mutant Lung Cancer The U.S. Food and Drug Administration (FDA) and China’s Center for Drug Evaluation (CDE) have granted Breakthrough Therapy Designation to sevabertinib for first-line…












